Rockwell Medical Stock Forecast, Price & News

-0.01 (-1.10 %)
(As of 04/20/2021 12:00 AM ET)
Today's Range
Now: $0.90
50-Day Range
MA: $1.19
52-Week Range
Now: $0.90
Volume1.29 million shs
Average Volume2.00 million shs
Market Capitalization$84.00 million
P/E RatioN/A
Dividend YieldN/A
Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Rockwell Medical logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:RMTI
Year FoundedN/A



Sales & Book Value

Annual Sales$61.30 million
Book Value$0.32 per share


Net Income$-34,130,000.00


Market Cap$84.00 million
Next Earnings Date5/10/2021 (Estimated)


Rockwell Medical: Q4 Earnings Insights
March 31, 2021 |
Rockwell Medical's Earnings: A Preview
March 30, 2021 |
RMTI May 2021 1.000 call
March 22, 2021 |
RMTI Mar 2021 1.000 call
March 9, 2021 |
RMTI Feb 2021 3.000 call
January 26, 2021 |
How to trade Rockwell Medical $RMTI With Risk Controls
January 23, 2021 |
See More Headlines


Overall MarketRank

1.31 out of 5 stars

Medical Sector

808th out of 2,018 stocks

Pharmaceutical Preparations Industry

386th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.01 (-1.10 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RMTI News and Ratings via Email

Sign-up to receive the latest news and ratings for RMTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Rockwell Medical (NASDAQ:RMTI) Frequently Asked Questions

Is Rockwell Medical a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rockwell Medical stock.
View analyst ratings for Rockwell Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Rockwell Medical?

Wall Street analysts have given Rockwell Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rockwell Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rockwell Medical's next earnings date?

Rockwell Medical is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Rockwell Medical

How were Rockwell Medical's earnings last quarter?

Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings data on Tuesday, March, 30th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. Rockwell Medical had a negative trailing twelve-month return on equity of 117.67% and a negative net margin of 47.23%.
View Rockwell Medical's earnings history

How has Rockwell Medical's stock price been impacted by Coronavirus?

Rockwell Medical's stock was trading at $2.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RMTI shares have decreased by 68.8% and is now trading at $0.8976.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RMTI?

1 analysts have issued 12-month target prices for Rockwell Medical's shares. Their forecasts range from $5.50 to $5.50. On average, they expect Rockwell Medical's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 512.7% from the stock's current price.
View analysts' price targets for Rockwell Medical
or view top-rated stocks among Wall Street analysts.

Who are Rockwell Medical's key executives?

Rockwell Medical's management team includes the following people:
  • Dr. Ajay Gupta, Chief Scientific Officer (Age 63, Pay $570.68k)
  • Dr. Russell H. Ellison M.Sc., M.D., MSc., Pres, CEO & Director (Age 73)
  • Mr. Russell L. Skibsted M.B.A., Exec. VP, CFO & Chief Bus. Officer (Age 62)
  • Mr. Michael DeYoung, VP of Operations
  • Mr. Paul E. McGarry, VP, Corp. Controller & Principal Accounting Officer (Age 53)
  • Michael Costello, Gen. Counsel
  • Mr. James A. McCarthy, Sr. VP of Bus. & Corp. Devel.
  • Mr. Timothy T. Chole, Sr. VP of Sales & Marketing
  • Dr. Raymond Dennis Pratt, Chief Devel. Officer (Age 70)
  • Mr. David J. Kull, Sec. (Age 53)

What is Robert L. Chioini's approval rating as Rockwell Medical's CEO?

6 employees have rated Rockwell Medical CEO Robert L. Chioini on Robert L. Chioini has an approval rating of 22% among Rockwell Medical's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Rockwell Medical's key competitors?

What other stocks do shareholders of Rockwell Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

What is Rockwell Medical's stock symbol?

Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."

Who are Rockwell Medical's major shareholders?

Rockwell Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Chicago Capital LLC (0.03%). Company insiders that own Rockwell Medical stock include Angus W Smith, David S Richmond, Russell H Ellison and Stuart M Paul.
View institutional ownership trends for Rockwell Medical

Which major investors are buying Rockwell Medical stock?

RMTI stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have bought Rockwell Medical stock in the last two years include Angus W Smith, David S Richmond, Russell H Ellison, and Stuart M Paul.
View insider buying and selling activity for Rockwell Medical
or or view top insider-buying stocks.

How do I buy shares of Rockwell Medical?

Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rockwell Medical's stock price today?

One share of RMTI stock can currently be purchased for approximately $0.90.

How much money does Rockwell Medical make?

Rockwell Medical has a market capitalization of $84.00 million and generates $61.30 million in revenue each year. The company earns $-34,130,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Rockwell Medical have?

Rockwell Medical employs 300 workers across the globe.

What is Rockwell Medical's official website?

The official website for Rockwell Medical is

Where are Rockwell Medical's headquarters?

Rockwell Medical is headquartered at 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601.

How can I contact Rockwell Medical?

Rockwell Medical's mailing address is 411 HACKENSACK AVENUE SUITE 501, HACKENSACK NJ, 07601. The company can be reached via phone at 248-960-9009 or via email at [email protected]

This page was last updated on 4/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.